Neuronetics, Inc.

STIM

Nasdaq; healthcare; SIC 3841, Surgical & Medical Instruments & Apparatus; CIK 0001227636

C

middle fifth of 370 graded peers in healthcare

rank 206 of 370; percentile 55.6; sampling error 2.5 points; lower is stronger

A B C D E

C, the tortoise



Scoreboard


Profitability	C percentile 47.0
Solvency	D percentile 67.5
Growth and financing	B percentile 34.7
Reliability	0.87 AUC filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$120M to $591M assets total assets $141.6M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: distress
Inputs computable	8 of 14
Graded from	filings received through Mar 17, 2026 223 days before the rescan; latest periodic filing 10-Q received Aug 11, 2026
Last close	$2.10 2026-10-23; market equity $160.4M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 17, 2026

Neuronetics, Inc. (the "Company" or "Neuronetics" or the "Registrant") believes that mental health is as important as physical health. As a global leader in neuroscience, the Company is delivering more treatment options to patients and healthcare providers by offering exceptional in-office treatments that produce extraordinary results.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight


Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 47.0						
Gross profitability	51.1%	32.3%		22.9	368	2025-12-31
Return on invested capital	not computable	9.3%				
one or more required annual facts are missing						
Accruals ratio	(13.2%)	(6.6%)		33.4	807	2025-12-31
Gross margin stability, five years	10.9 pts	2.8 pts		84.6	242	2025-12-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Solvency, sleeve percentile 67.5						
Twelve-month failure probability	not computable	0.07%				
latest liabilities, cash plus short-term investments, book equity, and shares are required						
Altman Z double-prime	(10.42)	(0.33)		63.6	752	2025-12-31
Net debt to EBITDA	not computable	1.82x				
EBITDA must exceed $100,000						
Interest coverage	not computable	(4.51x)				
latest aligned inputs end 2024-12-31; latest annual assets end 2025-12-31						
Current ratio	2.02x	2.94x		71.4	834	2025-12-31
Growth and financing, sleeve percentile 34.7						
Revenue growth, three-year compound	31.8%	10.1%		20.6	413	2025-12-31
Free cash flow growth, three-year compound	not computable	10.9%				
current FCF must be positive and base FCF must exceed $100,000						
Reinvestment rate	not computable	37.1%				
one or more required annual facts are missing						
Asset growth, three years	6.6%	2.1%		37.9	700	2025-12-31
Net share issuance, one year	5.3%	2.5%		45.7	636	2026-03-10

Among 370 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
201	Roivant Sciences Ltd. (ROIV)	54.2	C	fortress balance sheet
202	Emergent BioSolutions Inc. (EBS)	54.5	C	
203	Teladoc Health, Inc. (TDOC)	54.7	C	fortress balance sheet
204	Regenxbio Inc. (RGNX)	55.0	C	short runway
205	Abbott Laboratories (ABT)	55.3	C	
206	Neuronetics, Inc. (STIM)	55.6	C	
207	ELI Lilly & Co. (LLY)	55.8	C	
208	AdaptHealth Corp. (AHCO)	56.1	C	
209	Inogen Inc. (INGN)	56.4	C	fortress balance sheet
210	Aquestive Therapeutics, Inc. (AQST)	56.6	C	
211	Cooper Companies, Inc. (COO)	56.9	C	

What the price implies

at the 2026-10-23 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	4.0%	7.7%	48
Distance from 52-week high	(36.1%)	(31.4%)	41
EBIT to enterprise value	(15.5%)	(1.5%)	27
Free cash flow yield	(13.2%)	(1.0%)	28
Book value to price	0.11	0.28	28
Sales to price	0.93	0.30	81

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Composite equity issuance, five years	109.8%	20.5%	80
Relative strength against the sector, log excess return	(0.17)	(0.14)	48

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score 4 of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$19.2M
Operating cash flow, four quarters	-$10.3M
Months of runway	22.4
Days since last periodic filing	76 (10-Q received Aug 11, 2026)
Median daily dollar volume, 63 sessions	$2.4M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$72.3M	2025-12-31	2026-03-17	10-K	26-029004
2	assets	us-gaap:Assets	$141.6M	2025-12-31	2026-03-17	10-K	26-029004
3	net income	us-gaap:NetIncomeLoss	-$39.0M	2025-12-31	2026-03-17	10-K	26-029004
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$20.4M	2025-12-31	2026-03-17	10-K	26-029004
5	assets	us-gaap:Assets	$140.9M	2024-12-31	2026-03-17	10-K	26-029004
6	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$149.2M	2025-12-31	2026-03-17	10-K	26-029004
7	gross profit	us-gaap:GrossProfit	$54.2M	2024-12-31	2026-03-17	10-K	26-029004
8	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$74.9M	2024-12-31	2026-03-17	10-K	26-029004
9	gross profit	us-gaap:GrossProfit	$51.7M	2023-12-31	2026-03-17	10-K	26-029004
10	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$71.3M	2023-12-31	2026-03-17	10-K	26-029004
11	gross profit	us-gaap:GrossProfit	$49.7M	2022-12-31	2025-03-27	10-K	25-003833
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$65.2M	2022-12-31	2025-03-27	10-K	25-003833
13	gross profit	us-gaap:GrossProfit	$43.7M	2021-12-31	2024-03-08	10-K	24-002772
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$55.3M	2021-12-31	2024-03-08	10-K	24-002772
15	current assets	us-gaap:AssetsCurrent	$61.6M	2025-12-31	2026-03-17	10-K	26-029004
16	current liabilities	us-gaap:LiabilitiesCurrent	$30.5M	2025-12-31	2026-03-17	10-K	26-029004
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$458.8M	2025-12-31	2026-03-17	10-K	26-029004
18	operating income	us-gaap:OperatingIncomeLoss	-$31.4M	2025-12-31	2026-03-17	10-K	26-029004
19	book equity	us-gaap:StockholdersEquity	$22.4M	2025-12-31	2026-03-17	10-K	26-029004
20	liabilities	us-gaap:Liabilities	$115.3M	2025-12-31	2026-03-17	10-K	26-029004
21	total debt	us-gaap:LongTermDebt	$65.8M	2025-12-31	2026-03-17	10-K	26-029004
22	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$28.1M	2025-12-31	2026-03-17	10-K	26-029004
23	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$3.5M	2025-12-31	2026-03-17	10-K	26-029004
24	operating income	us-gaap:OperatingIncomeLoss	-$34.6M	2024-12-31	2026-03-17	10-K	26-029004
25	interest expense	us-gaap:InterestExpense	$7.3M	2024-12-31	2025-03-27	10-K	25-003833
26	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$801,000	2025-12-31	2026-03-17	10-K	26-029004
27	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$31.0M	2024-12-31	2026-03-17	10-K	26-029004
28	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$1.5M	2024-12-31	2026-03-17	10-K	26-029004
29	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$32.0M	2023-12-31	2026-03-17	10-K	26-029004

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

30	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$2.4M	2023-12-31	2026-03-17	10-K	26-029004
31	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$30.7M	2022-12-31	2025-03-27	10-K	25-003833
32	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$3.3M	2022-12-31	2025-03-27	10-K	25-003833
33	assets	us-gaap:Assets	$115.8M	2023-12-31	2025-03-27	10-K	25-003833
34	assets	us-gaap:Assets	$116.9M	2022-12-31	2024-03-08	10-K	24-002772
35	shares outstanding	dei:EntityCommonStockSharesOutstanding	69,276,593	2026-03-10	2026-03-17	10-K	26-029004
36	shares outstanding	dei:EntityCommonStockSharesOutstanding	65,814,512	2025-03-18	2025-03-27	10-K	25-003833

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.